NFGH
Nan Fung Group Holdings Portfolio holdings
AUM
$63.4M
1-Year Return
35.61%
This Quarter Return
+5.6%
1 Year Return
+35.61%
3 Year Return
+215.98%
5 Year Return
–
10 Year Return
–
AUM
$63.4M
AUM Growth
-$59.2M
(-48%)
Cap. Flow
-$61M
Cap. Flow
% of AUM
-96.22%
Top 10 Holdings %
Top 10 Hldgs %
87.5%
Holding
35
New
–
Increased
–
Reduced
3
Closed
15
Top Buys
No buys this quarter
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$9.4M |
| 2 |
Zai Lab
ZLAB
|
$9.17M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
$6.61M |
| 4 |
Protagonist Therapeutics
PTGX
|
$5.87M |
| 5 |
Soleno Therapeutics
SLNO
|
$5.69M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Materials | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Mirum Pharmaceuticals
MIRM
$3.73B
| – | – |
-146,765
| Closed | -$6.61M |
|
27
Merus
MRUS
$5.01B
| – | – |
-120,038
| Closed | -$5.05M |
|
|
28
Protagonist Therapeutics
PTGX
$3.71B
| – | – |
-121,400
| Closed | -$5.87M |
|
|
29
Soleno Therapeutics
SLNO
$3.7B
| – | – |
-79,650
| Closed | -$5.69M |
|
30
Tourmaline Bio
TRML
$645M
| – | – |
-227,090
| Closed | -$3.45M |
|
|
VRNA
31
Verona Pharma
VRNA
$9.19B
| – | – |
-147,990
| Closed | -$9.4M |
|
32
Xenon Pharmaceuticals
XENE
$2.98B
| – | – |
-158,605
| Closed | -$5.32M |
|
|
33
Zai Lab
ZLAB
$3.34B
| – | – |
-253,675
| Closed | -$9.17M |
|
34
Exelixis
EXEL
$10.1B
| – | – |
-64,200
| Closed | -$2.37M |
|
|
CLYM
35
Climb Bio, Inc. Common Stock
CLYM
$158M
| – | – |
-463,654
| Closed | -$566K |
|